Lilly Left Nektar Drug 'Damaged Goods,' Jury Told At Trial End
Eli Lilly & Co. turned Nektar Therapeutics' autoimmune-disease drug Rezpeg into "damaged goods" by breaching the companies' co-development deal and delaying the medication's development in favor of a competing drug the...To view the full article, register now.
Already a subscriber? Click here to view full article